Skip to Main Content

Filter:

Editors Choice

1 Results

Original Article Non-Small Cell Lung Cancer
Open Access
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Journal of Thoracic Oncology
Vol. 16Issue 12p2091–2108Published online: September 16, 2021
- D. Ross Camidge
- Hye Ryun Kim
- Myung-Ju Ahn
- James C.H. Yang
- Ji-Youn Han
- Maximilian J. Hochmair
- and others
Cited in Scopus: 58
In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor–naive advanced ALK-positive NSCLC, brigatinib exhibited superior progression-free survival (PFS) versus crizotinib in the two planned interim analyses. Here, we report the final efficacy, safety, and exploratory results.